Demyelinating syndrome in systemic sclerosis and neuromyelitis optica.
Demyelinating syndrome
Neuromyelitis optica
Systemic lupus erythematous
Systemic sclerosis
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
14 Oct 2019
14 Oct 2019
Historique:
received:
20
02
2019
accepted:
20
09
2019
entrez:
15
10
2019
pubmed:
15
10
2019
medline:
21
12
2019
Statut:
epublish
Résumé
This article reports a case diagnosis of a 44-year-old female who presented with intractable hiccups and vomit complicated with an acute onset of paraplegia. Transverse myelitis was evident on MRI and serological studies were consistent with Neuromyelitis Optica (NMO) based on NMO-IgG sero-positivity. Further studies revealed positive ANA, anti-RNA polymerase III autoantibodies, and Scl-70, leading to a concurrent diagnosis of systemic sclerosis (SSc). The coexistence of these two disease processes and their underlying clinical manifestations and therapeutic interventions are seldom reported in literature and are worth reporting. The patient was treated with high dose steroids, and subsequently developed malignant hypertension and acute renal failure, later identified on biopsy as steroids-induced scleroderma renal crisis. Although Neuromyelitis Optica spectrum disorder (NMOSD) has often been associated with various collagen and autoimmune diseases, the coexistence of NMOSD and SSc presented a challenge where the patient underwent aggressive physical therapy and necessitated an intervention with Rituximab to achieve an appropriate clinical response. We have received a written consent forms from the participant in our study, and we have them on file in case they are requested. We have also received the patient's written consent for the data and images presented in this article. This article expands on NMOSD associated autoimmune diseases. Systemic Sclerosis is an insidious disease that is often diagnosed late as not all patients often report skin manifestation. The finding suggests that patients presenting with acute neurological manifestations get tested for NMO-IgG/AQP-4 antibodies and other immunological studies based on clinical findings.
Sections du résumé
BACKGROUND
BACKGROUND
This article reports a case diagnosis of a 44-year-old female who presented with intractable hiccups and vomit complicated with an acute onset of paraplegia. Transverse myelitis was evident on MRI and serological studies were consistent with Neuromyelitis Optica (NMO) based on NMO-IgG sero-positivity. Further studies revealed positive ANA, anti-RNA polymerase III autoantibodies, and Scl-70, leading to a concurrent diagnosis of systemic sclerosis (SSc). The coexistence of these two disease processes and their underlying clinical manifestations and therapeutic interventions are seldom reported in literature and are worth reporting.
CASE PRESENTATION
METHODS
The patient was treated with high dose steroids, and subsequently developed malignant hypertension and acute renal failure, later identified on biopsy as steroids-induced scleroderma renal crisis. Although Neuromyelitis Optica spectrum disorder (NMOSD) has often been associated with various collagen and autoimmune diseases, the coexistence of NMOSD and SSc presented a challenge where the patient underwent aggressive physical therapy and necessitated an intervention with Rituximab to achieve an appropriate clinical response. We have received a written consent forms from the participant in our study, and we have them on file in case they are requested. We have also received the patient's written consent for the data and images presented in this article.
CONCLUSION
CONCLUSIONS
This article expands on NMOSD associated autoimmune diseases. Systemic Sclerosis is an insidious disease that is often diagnosed late as not all patients often report skin manifestation. The finding suggests that patients presenting with acute neurological manifestations get tested for NMO-IgG/AQP-4 antibodies and other immunological studies based on clinical findings.
Identifiants
pubmed: 31607267
doi: 10.1186/s12883-019-1472-6
pii: 10.1186/s12883-019-1472-6
pmc: PMC6790997
doi:
Substances chimiques
Autoantibodies
0
Immunologic Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
234Références
Neurology. 2005 Nov 8;65(9):1479-82
pubmed: 16275842
Autoimmun Rev. 2009 Dec;9(2):128-31
pubmed: 19389491
Ann Neurol. 1985 Jun;17(6):615-7
pubmed: 4026234
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
J Rheumatol. 2008 Jan;35(1):172-4
pubmed: 18176991
Rheumatol Int. 2015 Feb;35(2):243-53
pubmed: 24952418
Nat Clin Pract Rheumatol. 2008 Jul;4(7):381-6
pubmed: 18493269
Autoimmun Rev. 2017 Mar;16(3):244-252
pubmed: 28159705
Arch Neurol. 2004 Jan;61(1):126-8
pubmed: 14732630
Arch Neurol. 1992 Dec;49(12):1292-5
pubmed: 1333182
Lancet Neurol. 2007 Sep;6(9):805-15
pubmed: 17706564
J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1075-8
pubmed: 18420727
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S204-15
pubmed: 20176259
Clin Exp Dermatol. 1990 Mar;15(2):91-4
pubmed: 2161303
J Neurol Sci. 2012 Feb 15;313(1-2):48-53
pubmed: 22036215
Mult Scler. 2015 Jun;21(7):845-53
pubmed: 25921037